A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride (HCl) Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD) in Fed Condition

Rhodes Pharmaceuticals, L.P.2 个研究点分布在 1 个国家目标入组 10 人开始时间: 2016年7月30日最近更新: 2021年11月24日

适应症

干预措施

试验速览

阶段: 4 期
状态: 已完成
发起方: Rhodes Pharmaceuticals, L.P.
入组人数: 10
试验地点: 2
主要终点: AUC(0-t)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.

详细描述

This will be a multi-center, open-label, single-dose, study to assess the pharmacokinetics of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules in male and female children 4 to under 6 years of age with ADHD in fed condition.

Screening Procedures: After obtaining written informed consent from parents, subjects will undergo a complete medical and medication history, demographic data (including sex, age, race, ethnicity, body weight (kg), height (cm), Body Mass Index (BMI) (kg/m2), physical examination, vital signs evaluation (sitting blood pressure, pulse rate, respiration rate, temperature and pulse oximetry), resting 12-lead electrocardiogram (ECG), clinical laboratory tests and concomitant medication within 28 days prior to receiving study drug. On Day 1: subjects will receive a single oral dose of Aptensio XR®.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Other
盲法: None

入排标准

年龄范围: 4 Years 至 5 Years（Child）
性别: All
接受健康志愿者: 否

入选标准

•Patient is a male or female between the ages of 4 and under 6 years old.
•Patient has a history consistent with ADHD, meets the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for ADHD, inattentive, hyperactivity or combined.
•Patient must meet criteria for ADHD diagnosis on Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime (KSADS-PL) and clinical interview by experienced clinician; symptoms must have been present for at least 6 months.
•Subject has had prior behavioral treatment or subject's symptoms are severe enough to warrant treatment without prior behavioral treatment, and patient is on a stable dose of either immediate-release or extended-release methylphenidate.
•Subject must have age- and sex-adjusted ratings of ≥ 90th percentile Total Score on the Attention Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Preschool Version, a Clinical Global Impressions -Severity Score of ≥4 and a Child Global Assessment Scale rating of <65 after methylphenidate washout and prior to obtaining pharmacokinetic samples. Ratings may be completed via telephone on day-
•Parents or guardians of patients must have the ability to read and understand the language in which the Informed Consent is written and are mentally and physically competent to provide written informed consents for their child.
•Patient and/or parent are/is able to understand English in order to provide assent and is otherwise able to comply with the study protocol.

排除标准

•Patient has allergy to methylphenidate or amphetamines, or history of serious adverse reaction to methylphenidate.
•Patient has a history of tension, agitation, glaucoma, thyrotoxicosis, tachyarrhythmias or severe angina pectoris or patient with serious or unstable medical illness such as asthma, diabetes or seizures.
•A history of motor or vocal tics or Tourette's syndrome
•Patient is receiving monoamine oxidase inhibitors, anticonvulsants (phenobarbital, phenytoin, primidone), coumarin anticoagulants, presser agents, guanethidine, tricyclic antidepressants (imipramine, desipramine, selective serotonin inhibitors (SSRIs), or herbal remedies (e.g., melatonin).
•Patient has serious hypertension.
•Patient has a history of disorders of the sensory organs, particularly deafness, severe or profound retardation.
•Patient has any other unstable psychiatric condition requiring treatment.
•Patient is at risk for substance abuse.
•Evidence of current physical, sexual, or emotional abuse
•Living with anyone who currently abuses stimulants or cocaine
•History of bipolar disorder in both biological parents

研究组 & 干预措施

Methylphenidate HCl ER Capsules, 10 mg

Experimental

Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once

干预措施: Methylphenidate HCl ER Capsules, 10 mg (Drug)

Methylphenidate HCl ER Capsules, 15 mg

Experimental

Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once

干预措施: Methylphenidate HCl ER Capsules, 15 mg (Drug)

Methylphenidate HCl ER Capsules, 20 mg

Experimental

Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once

干预措施: Methylphenidate HCl ER Capsules, 20 mg (Drug)